Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325693 | 0.83 | HPGD (0.66) | TSHRHPGDCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24767635 | 0.83 | CHRNB2 (0.48) | TSHRHPGDCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1818244 | 0.83 | TSHR (0.43) | TSHRHPGDCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25634656 | 0.80 | CHRNB2 (0.46) | HPGDCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1491198 | 0.80 | CHRNB2 (0.46) | TSHRHPGDCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1822594 | 0.78 | ATM (0.42) | TSHRHPGDCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL473576 | 0.77 | TSHR (0.68) | TSHRHPGDKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL264775 | 0.77 | TSHR (0.68) | TSHRHPGDKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL12670558 | 0.77 | TSHR (0.68) | TSHRHPGDKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1073143 | 0.77 | TSHR (0.68) | TSHRHPGDKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | TSHR 1695/4885HPGD 83/4885CHRNB2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.